Strengthening Preclinical Confidence in Dermatology Drug Development: Using Translational Pharmacology Models to Validate Targets Before Clinical Trials
- Validating inflammatory pathways through translational in vivo models, including inducible skin challenge systems that allow early proof-of-mechanism testing before committing to full patient trials
- Benchmarking multi-pathway modulation against known therapeutic mechanisms to differentiate biological effects and prioritize the most promising targets for further development
- Using early translational pharmacology and experimental therapeutic studies to inform clinical strategy, generating mechanistic evidence that strengthens regulatory discussions and supports progression toward Phase II trials in indications such as HS